Literature DB >> 31241387

First clinical experiences with a high field 1.5 T MR linac.

Anders S Bertelsen1, Tine Schytte2,3, Pia K Møller2,4, Faisal Mahmood1,3, Hans L Riis1,2, Karina L Gottlieb1, Søren N Agergaard1, Lars Dysager2, Olfred Hansen2,3, Janne Gornitzka2, Elisabeth Veldhuizen1, Dean B ODwyer1, Rasmus L Christiansen1,3, Morten Nielsen1, Henrik R Jensen1, Carsten Brink1,3, Uffe Bernchou1,3.   

Abstract

Purpose: A 1.5 T MR Linac (MRL) has recently become available. MRL treatment workflows (WF) include online plan adaptation based on daily MR images (MRI). This study reports initial clinical experiences after five months of use in terms of patient compliance, cases, WF timings, and dosimetric accuracy. Method and materials: Two different WF were used dependent on the clinical situation of the day; Adapt To Position WF (ATP) where the reference plan position is adjusted rigidly to match the position of the targets and the OARs, and Adapt To Shape WF (ATS), where a new plan is created to match the anatomy of the day, using deformable image registration. Both WFs included three 3D MRI scans for plan adaptation, verification before beam on, and validation during IMRT delivery. Patient compliance and WF timings were recorded. Accuracy in dose delivery was assessed using a cylindrical diode phantom.
Results: Nineteen patients have completed their treatment receiving a total of 176 fractions. Cases vary from prostate treatments (60Gy/20F) to SBRT treatments of lymph nodes (45 Gy/3F) and castration by ovarian irradiation (15 Gy/3F). The median session time (patient in to patient out) for 127 ATPs was 26 (21-78) min, four fractions lasted more than 45 min due to additional plan adaptation. For the 49 ATSs a median time of 12 (1-24) min was used for contouring resulting in a total median session time of 42 (29-91) min. Three SBRT fractions lasted more than an hour. The time on the MRL couch was well tolerated by the patients. The median gamma pass rate (2 mm,2% global max) for the adapted plans was 99.2 (93.4-100)%, showing good agreement between planned and delivered dose.
Conclusion: MRL treatments, including daily MRIs, plan adaptation, and accurate dose delivery, are possible within a clinically acceptable timeframe and well tolerated by the patients.

Entities:  

Mesh:

Year:  2019        PMID: 31241387     DOI: 10.1080/0284186X.2019.1627417

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  29 in total

1.  Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.

Authors:  Brigid A McDonald; Sastry Vedam; Jinzhong Yang; Jihong Wang; Pamela Castillo; Belinda Lee; Angela Sobremonte; Sara Ahmed; Yao Ding; Abdallah S R Mohamed; Peter Balter; Neil Hughes; Daniela Thorwarth; Marcel Nachbar; Marielle E P Philippens; Chris H J Terhaard; Daniel Zips; Simon Böke; Musaddiq J Awan; John Christodouleas; Clifton D Fuller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-12-16       Impact factor: 7.038

2.  Comparison of radiographer interobserver image registration variability using cone beam CT and MR for cervix radiotherapy.

Authors:  John Rodgers; Rosie Hales; Lee Whiteside; Jacqui Parker; Louise McHugh; Anthea Cree; Marcel van Herk; Ananya Choudhury; Peter Hoskin; Alan McWilliam; Cynthia L Eccles
Journal:  Br J Radiol       Date:  2020-06-16       Impact factor: 3.039

3.  Clinical Implementation and Initial Experience With a 1.5 Tesla MR-Linac for MR-Guided Radiation Therapy for Gynecologic Cancer: An R-IDEAL Stage 1 and 2a First in Humans Feasibility Study of New Technology Implementation.

Authors:  David S Lakomy; Jinzhong Yang; Sastry Vedam; Jihong Wang; Belinda Lee; Angela Sobremonte; Pamela Castillo; Neil Hughes; Mustefa Mohammedsaid; Anuja Jhingran; Ann H Klopp; Seungtaek Choi; C David Fuller; Lilie L Lin
Journal:  Pract Radiat Oncol       Date:  2022-03-09

4.  Impact of varying air cavity on planning dosimetry for rectum patients treated on a 1.5 T hybrid MR-linac system.

Authors:  Paola Godoy Scripes; Ergys Subashi; Sarah Burleson; Jiayi Liang; Paul Romesser; Christopher Crane; James Mechalakos; Margie Hunt; Neelam Tyagi
Journal:  J Appl Clin Med Phys       Date:  2020-05-23       Impact factor: 2.102

5.  Treatment plan quality during online adaptive re-planning.

Authors:  Janita E van Timmeren; Madalyne Chamberlain; Jérôme Krayenbuehl; Lotte Wilke; Stefanie Ehrbar; Marta Bogowicz; Callum Hartley; Mariangela Zamburlini; Nicolaus Andratschke; Helena Garcia Schüler; Matea Pavic; Panagiotis Balermpas; Chaehee Ryu; Matthias Guckenberger; Stephanie Tanadini-Lang
Journal:  Radiat Oncol       Date:  2020-08-21       Impact factor: 3.481

Review 6.  MR-Guided Radiotherapy for Prostate Cancer.

Authors:  Boris R Tocco; Amar U Kishan; Ting Martin Ma; Linda G W Kerkmeijer; Alison C Tree
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

7.  Evaluation of daily online contour adaptation by radiation therapists for prostate cancer treatment on an MRI-guided linear accelerator.

Authors:  Thomas Willigenburg; Daan M de Muinck Keizer; Max Peters; An Claes; Jan J W Lagendijk; Hans C J de Boer; Jochem R N van der Voort van Zyp
Journal:  Clin Transl Radiat Oncol       Date:  2021-01-14

Review 8.  Medical physics challenges in clinical MR-guided radiotherapy.

Authors:  Christopher Kurz; Giulia Buizza; Guillaume Landry; Florian Kamp; Moritz Rabe; Chiara Paganelli; Guido Baroni; Michael Reiner; Paul J Keall; Cornelis A T van den Berg; Marco Riboldi
Journal:  Radiat Oncol       Date:  2020-05-05       Impact factor: 3.481

9.  International survey; current practice in On-line adaptive radiotherapy (ART) delivered using Magnetic Resonance Image (MRI) guidance.

Authors:  H A McNair; T Wiseman; E Joyce; B Peet; R A Huddart
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-09-14

10.  Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer.

Authors:  A Hunt; I Hanson; A Dunlop; H Barnes; L Bower; J Chick; C Cruickshank; E Hall; T Herbert; R Lawes; D McQuaid; H McNair; A Mitchell; J Mohajer; T Morgan; U Oelfke; G Smith; S Nill; R Huddart; S Hafeez
Journal:  Clin Transl Radiat Oncol       Date:  2020-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.